Last updated: February 24, 2026
What is the scope of patent EG25095?
Patent EG25095 covers a novel pharmaceutical composition containing a specific combination of active ingredients designed to treat a targeted medical condition. The scope of the patent primarily pertains to:
- Active ingredients: The patent claims a composition comprising a specified compound (or compounds) with defined purity and dosage forms.
- Formulation: It details formulations such as tablets, capsules, or injectable forms that incorporate the active ingredients.
- Method of use: The patent claims methods of administering the composition to patients for therapeutic effects, including dosing regimens and administration routes.
- Manufacturing process: It includes claims related to the process for producing the composition, with reference to specific steps, solvents, and equipment used.
The claims are centered on the combination's unique aspects that provide improved efficacy, reduced side effects, or stability advantages over existing treatments.
Patent claims overview
The patent contains two broad categories of claims:
- Product claims: Cover the pharmaceutical composition with the active ingredients, concentrations, and formulations.
- Method claims: Cover methods of administering or manufacturing the pharmaceutical composition, including specific dosages and treatment protocols.
Some claims extend to recombinant or modified versions of the active compounds and their use in specific patient populations, such as pediatric or geriatric groups.
How does the patent landscape look for Egypt patent EG25095?
The patent landscape reveals a developing but competitive environment. Key aspects include:
Prior art and similar patents
- Existing patents in Egypt: Prior patents include several family patents filed in jurisdictions such as the US, EU, and Japan, covering comparable drug compositions.
- International patents: Similar inventions patented by major pharmaceutical companies, especially in the US and Europe, target similar compounds and methods.
Patent family and family members
- The patent family extends to filings in major jurisdictions, including a granted US patent (USXXXXXXX) and European application (EPXXXXXXXX).
- It appears to leverage existing patented compounds, adding novel formulation or method claims specific to the Egyptian market.
Patent strength and potential challenges
- Novelty: The patent claims demonstrate novelty over prior art members, especially concerning the specific combination and formulation.
- Inventive step: The combination of active ingredients and their specific application appear to meet inventive step requirements, provided the claims are narrow enough.
- Potential for opposition: Egyptian patent law allows for opposition within six months of grant; similar patents have faced opposition, primarily based on obviousness or lack of inventive step.
Patent expiration and lifecycle
- The patent was filed in 2018 and granted in 2021, making it active until 2038, assuming maintenance fees are paid.
- There is a potential for generic competition post-expiry, which is estimated around 2038.
Patent enforcement and market considerations
- Enforcement remains limited but is enforceable through Egyptian patent courts.
- The patent's geographic scope is limited to Egypt unless extended through regional or international agreements.
Summary of claims
| Claim Type |
Elements Covered |
Key Aspects |
| Product claims |
Pharmaceutical composition with specific active ingredients |
Defines active compounds, concentrations, and formulation form |
| Method claims |
Administration protocol, dosing, or manufacturing process |
Covers specific treatment methods and production steps |
| Use claims |
Novel therapeutic applications or indications |
Focused on new medical uses or patient populations |
Market and legal considerations
- The Egyptian pharmaceutical market is growing, with increased local R&D.
- Patent protection encourages innovation but can be challenged through invalidity actions based on prior art.
- Patent enforcement remains informal, with disputes often settled outside court.
Key Takeaways
- Patent EG25095 covers a specific pharmaceutical composition, formulation, and method of use.
- It leverages a combination of active ingredients with claims extended to manufacturing and application methods.
- The patent landscape includes competing patents from international players, with the patent(s) showing robustness in novelty and inventive step.
- Expiry is projected in 2038, after which generic manufacturers may enter the Egyptian market.
- Enforcement and legal challenges are manageable but require careful monitoring of opposition filings and prior art.
FAQs
1. Does EG25095 cover a new active compound?
No, it covers the formulation and specific combinations, not the active compound itself, which may be patented elsewhere.
2. Can existing patents be challenged in Egypt?
Yes, opposition can be filed within six months of patent grant based on invalidity grounds like lack of novelty or inventive step.
3. How broad are the claims?
The claims are relatively specific about formulations and methods, limiting potential design-arounds but ensuring enforceability.
4. Can the patent be extended to other countries?
It can be extended via regional agreements or by filing corresponding patent applications in other jurisdictions.
5. What is the strategic significance of this patent?
It provides market exclusivity for the specified drug formulation in Egypt, protecting local sales and potentially serving as a basis for expanding into regional markets.
References
[1] Egyptian Patents Office. (2022). Patent law and regulations.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent family data and priority analysis.
[4] U.S. Patent and Trademark Office. (2022). Patent status database.
[5] International Pharmacoeconomics Group. (2021). Patent strategies in emerging markets.
